PTD-DBM

2021 Q&A With Dr. Kang-Yell Choi: Update (9/14/21) I was recently able to conduct another Q&A with Dr. Kang-Yell Choi who gives the latest updates on his company below. Among the updates, Dr. Choi’s startup aimed at commercializing drugs which target the CXXC5 protein is now going by a new name, CK Regeon. FT: What’s…